Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 27

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 27
---
/or additional acquisitions, and may have a material negative effect on the market price of our securities. |

| • | Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. |

| • | As a foreign private issuer, we are not required to comply with many of the corporate governance standards 
 of NASDAQ applicable to companies incorporated in the United States.                                       |

| • | Your right to participate in any future rights offerings may be limited, which may cause dilution to your holdings. |

| • | Protections found in provisions under the United Kingdom City Code on Takeovers and Mergers may delay                                
 or discourage a takeover attempt, including attempts that may be beneficial to holders of our Ordinary Shares and Depositary Shares. |

| 14 |

Risks Related to the Equity Financing

It is not possible to predict the actual number of Depositary Shares, if any, we will sell under the Purchase Agreement, or the actual gross proceeds resulting from those sales or the dilution to you from those sales.

Pursuant to the Purchase Agreement,
the Selling Shareholder shall, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, purchase from
us up to $35.0 million of Depositary Shares, upon the terms and subject to the conditions and limitations set forth in the Purchase Agreement,
or the Commitment Amount, and, accordingly, we have registered 350,000,000,000 Ordinary Shares represented by 35,000,000 Depositary Shares
for issuance under the Purchase Agreement and resale pursuant to this prospectus, assuming that that $35.0 million of Depositary Shares
are issued and sold at a price of $1.00 per share (and excluding any Commitment Shares offered hereby). The Depositary Shares that may
be issued under the Purchase Agreement may be sold, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement,
by us to the Selling Shareholder at our discretion from time to time from the Commencement Date (as defined below) until the earliest
to occur of (i) the first day of the month next following the 36-month anniversary of the Commencement Date, (ii) the date on which the
Selling Shareholder shall have purchased the Commitment Amount, (iii) the ninetieth day after the date on which, pursuant to or within
the meaning of any bankruptcy law, we commence a voluntary case or any person commences a proceeding against us, in each case that is
not discharged or